Font: https://www.massgeneral.org/neurology/treatments-and-services/about-mog-es#:~:text=Mielina%20oligodendrocito%20glicoproteína%20(MOG)%20es,protectora%20que%20rodea%20los%20nervios.

MOG affects myelin, a substance that covers the fibers of the central nervous system and, therefore, the neurons.

Myelin oligodendrocyte glycoprotein disease is an autoimmune disorder in which the immune system mistakenly attacks myelin, leading to inflammation and destruction of this substance. It is a demyelinating disease of the central nervous system that has gained increasing interest in recent years. 

Although the epidemiology of MOG disease is a developing area of research, significant advances have been made in understanding the incidence, prevalence, risk factors, and clinical characteristics of this disease. 

To begin, you need to understand that MOG disease is an autoimmune condition that affects myelin, the substance that covers nerve fibers in the central nervous system. Although initially considered a variant of multiple sclerosis (MS), recent research has shown that MOG disease has distinctive features that differentiate it from MS. 

The identification of autoantibodies against the MOG protein has been fundamental for the recognition of this disease as a separate clinical entity.

Myelin oligodendrocyte glycoprotein (MOG) is a specific protein found on the surface of myelin-producing cells in the central nervous system. Although it has been known for some time, it has gained increasing interest in recent years due to its role in autoimmune diseases of the nervous system, such as multiple sclerosis and myelin oligodendrocyte glycoprotein disease (MOG-EM).

MOG is a transmembrane glycoprotein that belongs to the immunoglobulin family, and is expressed mainly on the surface of oligodendrocyte cells, which are responsible for producing myelin, an insulating substance that covers nerve fibers in the nervous system. central. 

The function of MOG under normal conditions is not completely elucidated, but it is believed to play an important role in stabilizing myelin and interacting with other myelin proteins and cells of the immune system. MOG is mainly expressed on the surface of oligodendrocyte cells, which are responsible for producing myelin in the central nervous system. 

Its amino acid sequence shows similarity to other myelin proteins, such as myelin basic protein (MBP) and proteolipid protein (PLP), which also play an important role in the formation and maintenance of myelin. The MOG is composed of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain of MOG contains an immunoglobulin region, which is crucial for its interaction with other proteins and cells of the immune system.

It has been postulated that MOG participates in the interaction between myelin layers and other myelin proteins, such as MBP and PLP, contributing to the stability and compaction of myelin. Furthermore, it has been suggested that MOG may be involved in cell signaling and the regulation of oligodendrocyte cell growth and differentiation. However, the precise mechanisms by which MOG exerts these functions are not completely clear and remain the subject of active research.

Myelin is an essential structure for the proper functioning of the nervous system, as it acts as an insulator for nerve fibers, surrounding the axons of neurons, providing several key benefits for the efficient transmission of nerve impulses. When myelin is damaged or destroyed, communication between nerve cells is affected, which can lead to a variety of neurological symptoms.

Myelin is a fatty substance that covers and insulates the axons of neurons in the central and peripheral nervous system. This myelin layer acts as an electrical insulator that allows efficient transmission of nerve impulses along nerve fibers. Myelin is produced by glial cells, including oligodendrocytes in the central nervous system and Schwann cells in the peripheral nervous system.

First of all, myelin increases the speed of conduction of nerve impulses along axons. This rapid speed is crucial for the rapid and efficient transmission of information through the nervous system, allowing rapid responses to environmental stimuli and precise coordination of body functions.

Additionally, myelin helps conserve energy by reducing the amount of energy needed to conduct nerve impulses. This is possible due to the arrangement of myelin in segments along the axon, known as "nodes of Ranvier", where the Saltatory conduction of nerve impulses allows efficient transmission with less energy expenditure.

In addition to its role as an electrical insulator, myelin also provides structural and metabolic support for neurons. It helps maintain the integrity and stability of axons, and facilitates nerve regeneration and repair after injury.

In the context of myelin oligodendrocyte glycoprotein disease, an autoimmune response occurs as we have mentioned in which the body's immune system mistakenly attacks myelin and the oligodendrocyte glycoprotein protein, leading to demyelination and inflammation of the system. central nervous This demyelination interferes with the transmission of nerve signals, which in turn can cause a wide range of neurological and non-neurological symptoms.

These responses may include the activation of immune cells, the release of proinflammatory cytokines, the formation of demyelinating lesions, and the alteration of the balance between neuroprotection and neurodegeneration in the nervous system.

Myelin oligodendrocyte glycoprotein disease is a rare autoimmune disorder that has been recognized relatively recently, and its specific pathophysiology and underlying mechanisms are not yet fully understood. However, it has been observed that autoantibodies directed against myelin oligodendrocyte glycoprotein are involved in the pathogenesis of the disease.

Symptoms

Symptoms of myelin oligodendrocyte glycoprotein disease can vary widely among patients, and can include motor, sensory, and cognitive symptoms. Some of the most common symptoms of the disease include muscle weakness, vision problems, difficulty walking, numbness or tingling in the extremities, fatigue, balance and coordination problems, pain, swallowing difficulties, speech problems, and changes in function. cognitive. These symptoms may appear suddenly or develop gradually over time.

In terms of clinical features, MOG disease presents with a wide range of neurological manifestations. The variability in the clinical presentation of MOG disease poses significant challenges in its diagnosis and management, underscoring the importance of a greater understanding of its epidemiological characteristics.

Muscle weakness is one of the most common symptoms of myelin oligodendrocyte glycoprotein disease. Patients may experience weakness in the arms, legs, or trunk muscles, which can make everyday tasks such as getting up from a chair, climbing stairs, or lifting heavy objects difficult. This muscle weakness can be intermittent or persistent, and can vary in severity.

Vision problems are also common in myelin oligodendrocyte glycoprotein disease. Patients may experience blurred vision, loss of vision in one or both eyes, double vision, eye pain, sensitivity to light, or changes in color perception. These vision problems can be temporary or persistent, and can affect the ability to perform visual tasks such as reading, driving, or watching television.

Difficulty walking is another common symptom of myelin oligodendrocyte glycoprotein disease. Patients may experience unsteadiness when walking, frequent tripping, difficulty lifting their feet, or dragging their feet when walking. These walking difficulties can increase the risk of falls and injuries, and can affect the patient's independence and quality of life.

Numbness or tingling in the extremities is a common sensory symptom in myelin oligodendrocyte glycoprotein disease. Patients may experience sensations of tingling, itching, burning, or numbness in the hands, feet, arms, or legs. These abnormal sensations may be intermittent or persistent, and may affect tactile sensitivity and motor coordination.

Fatigue is a common and debilitating symptom in myelin oligodendrocyte glycoprotein disease. Patients may experience an overwhelming feeling of tiredness that is not relieved by rest, which can interfere with daily activities and reduce quality of life. Fatigue can be one of the most disabling symptoms of the disease, and can hinder the ability to work, socialize, or perform physical activities.

Balance and coordination problems are common in myelin oligodendrocyte glycoprotein disease. Patients may experience difficulty maintaining balance, clumsy movements, lack of coordination, or involuntary tremors. These balance and coordination problems can increase the risk of falls and injuries, and can affect the patient's mobility and independence.

Pain is another common symptom in myelin oligodendrocyte glycoprotein disease. Patients may experience muscle, joint, back, neck, or nerve pain, which may be sharp, stabbing, dull, or burning. Pain can be intermittent or persistent, and can affect the patient's quality of life and emotional well-being.

Swallowing difficulties, also known as dysphagia, are a common symptom in myelin oligodendrocyte glycoprotein disease. Patients may experience difficulty swallowing liquids or food, a feeling of choking, coughing when swallowing, or a feeling of a blockage in the throat. Dysphagia may increase the risk of pulmonary aspiration and malnutrition, and may require therapeutic interventions to improve swallowing function.

Speech problems are another common symptom in myelin oligodendrocyte glycoprotein disease. Patients may experience difficulty articulating words, slurred vocalization, dysarthria, changes in tone of voice, or difficulty finding the right words. These speech problems can affect the patient's communication and social interaction, and can be a source of frustration and anxiety.

Changes in cognitive function are common in myelin oligodendrocyte glycoprotein disease. Patients may experience difficulty concentrating, memory problems, slowness in processing information, difficulty solving problems, or changes in personality. These cognitive changes can affect the ability to work, study, or perform everyday tasks, and can have a significant impact on the patient's quality of life.

In addition to these neurological symptoms, patients with myelin oligodendrocyte glycoprotein disease may also experience non-neurological symptoms, such as fever, headache, nausea, vomiting, loss of appetite, weight loss, sleep problems, dizziness, palpitations, or difficulty to control the bladder or bowel. These non-neurological symptoms may be the result of systemic inflammation or involvement of other body systems.

Myelin oligodendrocyte glycoprotein disease can cause a wide range of neurological and non-neurological symptoms, which can vary in severity and duration. The most common symptoms include muscle weakness, vision problems, difficulty walking, numbness or tingling in the extremities, fatigue, balance and coordination problems, pain, swallowing difficulties, speech problems, and changes in cognitive function. 

These symptoms can affect the patient's mobility, independence, quality of life, and emotional well-being, and may require therapeutic interventions to manage. If you experience any of these symptoms, it is important to see a doctor for proper diagnosis and treatment.

Epidemiology

In terms of epidemiology, MOG disease has been the subject of increasing interest in the medical and scientific community. Although MOG disease was previously considered rare, recent studies have revealed a more significant incidence and prevalence than initially thought. The incidence of MOG disease varies in different geographic regions, and it has been observed to affect individuals of all ages, including children and adults. Furthermore, MOG disease has been shown to have differences in age and sex distribution compared to MS, highlighting its importance as a distinct clinical entity.

Risk factor's

Regarding the risk factors associated with MOG disease, it has been observed that there are certain genetic and environmental predispositions that can influence the development of the disease. Epidemiological studies have investigated the possible association between MOG disease and factors such as exposure to viral infections, genetic susceptibility, and the influence of environmental factors on the development of the disease. Understanding these risk factors is crucial to identify population groups most likely to develop MOG disease and to implement appropriate preventive and management strategies.

Diagnosis

At the diagnostic level, the recognition of MOG disease as a separate clinical entity has led to the development of specific diagnostic criteria that allow it to be differentiated from other demyelinating diseases, such as MS. 

Laboratory tests for the detection of autoantibodies against the MOG protein have proven to be useful tools in the diagnosis of the disease. Autoantibodies against myelin oligodendrocyte glycoprotein can be detected in serum or cerebrospinal fluid by immunofluorescence or immunoblot techniques, which can confirm the diagnosis in patients with compatible clinical symptoms.

Additionally, MRI and spinal cord imaging may show demyelinating lesions that are characteristic of myelin oligodendrocyte glycoprotein disease, which may include areas of T2 hyperintensity, T1 contrast enhancement, and periventricular, cortical, or brainstem lesions. And other neuroimaging studies play a crucial role in the evaluation of patients with suspected MOG disease. These findings may be indicative of the disease and help differentiate it from other neurological disorders.

Treatment

With regard to treatment, the identification of MOG disease as a separate clinical entity has led to the development of specific therapeutic approaches aimed at its management. 

Although treatments for MOG disease share similarities with approaches used for MS, significant differences have been recognized in the response to certain immunomodulatory and immunosuppressive therapies, to control inflammation and reduce the activity of the immune system. 

Corticosteroids, intravenous immunoglobulin, rituximab, tocilizumab and other immunosuppressive agents can be used in the management of the disease, although evidence on the effectiveness of these treatments is limited and more studies are needed to establish specific treatment guidelines. 

Additionally, physical, occupational, and speech rehabilitation may be beneficial for patients with neurological and non-neurological symptoms of the disease.

Understanding the epidemiological characteristics of MOG disease is essential for the development of personalized therapeutic strategies that address the individual needs of patients.

In terms of prognosis, MOG disease has been observed to present a heterogeneous clinical course, with a subgroup of patients experiencing a monophasic course, while others present with recurrent relapses. 

The identification of prognostic factors associated with MOG disease, such as the presence of certain clinical manifestations and response to treatment, is essential to predict the course of the disease and to guide therapeutic decisions.

The recognition of MOG disease as a separate clinical entity has led to significant advances in the understanding of its epidemiology, which in turn has contributed to the development of more precise and personalized diagnostic and therapeutic strategies. 

As for future perspectives, more research is needed to better understand the pathophysiology, epidemiology, clinical presentation, diagnosis and treatment of myelin oligodendrocyte glycoprotein disease. Prospective studies and clinical trials are required to evaluate the efficacy and safety of immunomodulatory and immunosuppressive therapies in this disease, as well as to identify biomarkers that can predict treatment response and long-term prognosis. 

Furthermore, it is important to increase awareness about myelin oligodendrocyte glycoprotein disease among healthcare professionals, to facilitate early diagnosis and appropriate management of patients.

More research is needed to improve the understanding and management of myelin oligodendrocyte glycoprotein disease, and to improve the quality of life and prognosis of affected patients.

If you are interested in knowing more about these types of topics, visit our other articles through our blog at: https://eneviahealth.com/blog/